[Bora] Announcement of Board Resolution on Cash Capital Increase for Subsidiary Bora Pharmaceuticals USA Inc.

1. Name and nature of the target object (if preferred stock, also indicate agreed terms, such as dividend rate): Ordinary shares of Bora Pharmaceuticals USA Inc. 2. Date of occurrence: 115/5/11~115/5/11. 3. Date of board approval: May 11, 115 (Republic of China calendar year). 4. Other approval dates: Not applicable. 5. Transaction quantity, price per unit, and total transaction amount: This capital increase for Bora Pharmaceuticals USA Inc. is USD 122,500,000, all to be invested as capital reserve; transaction unit quantity and price per unit are not applicable. 6. Transaction counterparty and its relationship with the company (if the counterparty is an individual and not an affiliate of the company, their name may be omitted): (1) Transaction counterparty: Bora Pharmaceuticals USA Inc. (2) Relationship with the company: Wholly-owned subsidiary of the Company (100% holding). 7. If the counterparty is an affiliate, also announce the reason for selecting the affiliate as the counterparty, the previous owner, the relationship between the previous owner, the company, and the counterparty, the date of the previous transfer, and the transfer amount: Not applicable. 8. If the owner of the transaction target in the last five years was an affiliate of the company, also announce the date, price, and relationship with the company at the time of the transaction: Not applicable. 9. Matters related to the disposal of debt (including type of collateral attached to disposed debt, and if the disposed debt is owed to a related party, also announce the name of the related party and the book value of the debt disposed of to this related party): Not applicable. 10. Profit (or loss) from disposal (not applicable for acquisition of securities) (if deferred, list recognition status): Not applicable. 11. Delivery or payment terms (including payment period and amount), contract restrictions, and other important agreed matters: Execute cash capital increase according to the timeline of Bora Pharmaceuticals USA Inc.'s capital increase plan. 12. Method of transaction decision, basis for price determination, and decision-making unit: Approved by the company's Audit Committee and Board of Directors. 13. Net asset value per share of the company for which securities are acquired or disposed of: Not applicable. 14. Cumulative quantity, amount, shareholding ratio, and status of rights restrictions (e.g., pledge status) of securities held to date (including this transaction): (1) Cumulative quantity held: 500,000 shares. (2) Cumulative amount held: 17,337,375 thousand yuan. (3) Shareholding ratio: 100%. (4) Status of rights restrictions: None. 15. As of date, the proportion of securities investments (including this transaction) listed in Article 3 of the "Regulations Governing Acquisitions or Disposals of Assets by Public Companies" to the total assets and net equity attributable to the parent company in the most recent financial statements, and the amount of working capital in the most recent financial statements (Note 2): (1) Proportion to total assets in the parent company's most recent financial statements: 104.39%. (2) Proportion to net equity attributable to the parent company in the most recent financial statements: 216.34%. (3) Amount of working capital in the most recent financial statements: (3,793,203) thousand yuan. 16. Broker and brokerage fee: Not applicable. 17. Specific purpose or use of the acquisition or disposal: To supplement operations through this cash capital increase. 18. Opinion of dissenting directors for this transaction: None. 19. Is this transaction a related party transaction: Yes. 20. Date of supervisor's approval or audit committee's consent: May 11, 115 (Republic of China calendar year). 21. Did the accountant issue an unreasonable opinion for this transaction: Not applicable. 22. Name of accounting firm: Not applicable. 23. Name of accountant: Not applicable. 24. Accountant's practice certificate number: Not applicable. 25. Does it involve a change in the operating model: Yes. 26. Explanation of operating model change: Not applicable. 27. Transaction situation with the counterparty in the past year and expected in the next year: Not applicable. 28. Source of funds: Not applicable. 29. Date of previous announcement of material information on the same event: Not applicable. 30. Other descriptions: Approved by the Audit Committee and Board of Directors on May 11, 115, and authorized the Chairman to handle subsequent matters related to the capital increase, whether executed in one or multiple installments. Keywords: Material Information.